IDSA Practice Guidelines vs Residipok

Access the Infectious Diseases Society of America (IDSA) guidelines app anytime, anywhere! Download the app today and stay up-to-date on IDSA clinical guidelines, interactive tools, and new resources. The app contains features to search through guidelines, bookmark important pages and take notes on key information. Visit the IDSA app for new guidelines that are released throughout the year and new updates to existing guidelines. Disclaimer: The Infectious Diseases Society of America (IDSA) provides this app (“App)” for health care professionals only, and not the general public. The App is provided for informational purposes only, and it is not intended to provide medical or treatment advice and may not be treated as such by the user. As such, this App may not be relied upon for the purposes of medical diagnosis or as a recommendation for medical care or treatment. The information on this App is not a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this App is for general information purposes only.

Residipok is a pocket reference for licensed healthcare professionals, trainees, and medical students of accredited health-professions programs. TWO MODULES (v0.4) • MIC Lookup Choose a bacterium and an antibiotic to see the EUCAST v16.0 (2026) Clinical Breakpoint thresholds — S, I, R bands by clinical context (systemic, meningitis, urinary, high-dose). Enter an MIC value to categorise it. Special states clearly labelled when no breakpoint is published or the organism is intrinsically resistant. Built especially for pan-resistance scenarios where every threshold matters. • ESC Guideline Reference Structured Class / Level of Evidence summaries of recent ESC cardiology guidelines, covering acute coronary syndromes, heart failure, atrial fibrillation, hypertension, endocarditis, cardiomyopathies, valvular disease, pulmonary hypertension and embolism, peripheral arterial disease, dyslipidaemia, prevention, pregnancy, syncope, supraventricular tachycardia, and more. Each recommendation card links back to the original guideline on escardio.org. IMPORTANT — REFERENCE ONLY • Residipok is NOT a medical device. • It does NOT diagnose, treat, cure, or prevent disease. • It is NOT a substitute for clinical judgement or for the original published guideline / breakpoint table. • Always verify against the current EUCAST table and the latest ESC document before clinical reporting. Requires confirmation of HCP / trainee status on first launch. Sign-in by email, Apple, or Google. Sources: EUCAST Clinical Breakpoint Tables v16.0 (2026); European Society of Cardiology Clinical Practice Guidelines (2018–2024).